Muenster

• A Research Study to See How Switching from a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar … Ended
  2023-506084-34-00 5 2024-04-12 Type 2 Diabetes
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet … Ended
  2023-505414-15-00 4 2024-04-10 Dermatitis, Atopic
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended
  2023-505841-22-00 5 2024-04-04 Moderate to Severe Plaque Psoriasis
• A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W … Ended
  2023-507206-13-00 5 2024-03-14 Type 2 Diabetes
• A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Pa … Ended
  2023-507534-24-00 9 2024-03-06 Chronic Inducible Urticaria
• A study to test whether BI 685509 helps people with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liv … Ended
  2023-506083-13-00 4 2024-02-16 clinically significant portal hypertension (CSPH) in decompensated cir
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-502461-23-00 5 2024-02-15 Prurigo Nodularis
• A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007) Ended
  2023-503502-37-00 4 2024-01-24 Non segmental vitiligo
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• Ilofotase alfa for prevention of renal damage after cardiac surgery Ended
  2023-505859-45-00 4 2023-12-19 Risk for renal damage following open heart surgery
• A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended
  2022-502313-28-00 4 2023-12-14 Diabetic Peripheral Neuropathic Pain
• First Clinical Trial with activated regulatory T-cells in patients early after haematopoietic stem cell transplantation (HSCT) Ended
  2024-516599-14-00 7 2023-12-13 Leukaemia
• Functional Constipation: A Phase 2 Dose Finding Study Evaluating the Safety and Efficacy of Linaclotide in Pediatric Subjects 6 Months to Le … Ended
  2022-501947-34-00 4 2023-12-05 Functional Constipation (FC)
• This is a clinical trial (study), to be conducted in several clinical sites worldwide, of an oral study drug which will be investigated in a … Ended
  2023-503957-36-00 10 2023-12-04 Moderate-to-Severe pruritus in adult subjects with notalgia parestheti
• A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended
  2022-502370-17-00 4 2023-11-14 Hidradenitis suppurativa
• Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin Ended
  2023-503696-15-00 4 2023-11-10 sensorineural hearing loss (SNHL)
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S … Ended
  2023-505558-16-00 5 2023-10-24 Atopic Dermatitis
• A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe … Ended
  2022-501884-41-00 5 2023-09-29 Contrast enhancement in magnetic resonance imaging for assessment of c
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended
  2022-501476-25-00 5 2023-09-12 Atopic Dermatitis Eczema
• A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel … Ended
  2022-502048-10-00 4 2023-07-21 diabetic foot ulcers

Showing 505–528 of 608 trials